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The pace of innovation in radiation oncology is high and the window of opportunity 
for evaluation narrow. Financial incentives, industry pressure, and patients’ demand for 
high-tech treatments have led to widespread implementation of innovations before, or 
even without, robust evidence of improved outcomes has been generated. The standard 
phase I–IV framework for drug evaluation is not the most efficient and desirable framework 
for assessment of technological innovations. In order to provide a standard assessment 
methodology for clinical evaluation of innovations in radiotherapy, we adapted the surgical 
IDEAL framework to fit the radiation oncology setting. Like surgery, clinical evaluation of 
innovations in radiation oncology is complicated by continuous technical development, 
team and operator dependence, and differences in quality control. Contrary to surgery, 
radiotherapy innovations may be used in various ways, e.g., at different tumor sites 
and with different aims, such as radiation volume reduction and dose escalation. Also, 
the effect of radiation treatment can be modeled, allowing better prediction of potential 
benefits and improved patient selection. Key distinctive features of R-IDEAL include the 
important role of predicate and modeling studies (Stage 0), randomization at an early 
stage in the development of the technology, and long-term follow-up for late toxicity. We 
implemented R-IDEAL for clinical evaluation of a recent innovation in radiation oncology, 
the MRI-guided linear accelerator (MR-Linac). MR-Linac combines a radiotherapy linear 
accelerator with a 1.5-T MRI, aiming for improved targeting, dose escalation, and mar-
gin reduction, and is expected to increase the use of hypofractionation, improve tumor 
control, leading to higher cure rates and less toxicity. An international consortium, with 
participants from seven large cancer institutes from Europe and North America, has 
adopted the R-IDEAL framework to work toward coordinated, evidence-based introduc-
tion of the MR-Linac. R-IDEAL holds the promise for timely, evidence-based introduction 
of radiotherapy innovations with proven superior effectiveness, while preventing unnec-
essary exposure of patients to potentially harmful interventions.
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BAcKGrOUND
The pace of innovation in interventional oncology is high, and the 
window of opportunity for evaluation is narrow. Financial incen-
tives, industry pressure, and patients’ demand for “high-tech” 
treatments have led to widespread implementation of innovations 
without robust clinical evidence of improved outcomes (1). This 
is also the case in radiation oncology, where intensity-modulated 
radiotherapy (IMRT) was widely implemented before robust 
evidence of clinical superiority over standard treatment was 
generated, and for proton therapy, where high level (randomized) 
evidence of clinical superiority is lacking (2–4).
Ideally, before implementation, all radiotherapy innovations 
should be evaluated in a systematic manner, where—ultimately—
one compares effectiveness of the new technology against the 
standard treatment and evaluates whether it can lower toxicity, 
improve local control and survival, or save time or costs.
Until now, the phase 1, 2, and 3 trial framework has been 
applied to evaluate safety and efficacy of new radiotherapy 
interventions. However, this may not be the most efficient and 
desirable framework for assessment of radiotherapy innovations 
(5–7). For pharmaceuticals in oncology, phase 1 (i.e., dose escala-
tion) studies are typically performed among metastasized patients 
with limited life expectancy. This is not an optimal choice in the 
radiotherapy setting, where radiation-induced toxicities occur to 
up to a year or more and will be missed if only patients with lim-
ited life expectancy are included. Also, radiation dose, and dose 
to the organs at risk (OARs) in particular, cannot be standardized 
due to variation in anatomical disease distribution (5). When 
investigating a new radiotherapy treatment for early efficacy and 
toxicity (phase 2), a single-arm study is rather uninformative due 
to the high variability in patient and treatment-related factors that 
affect outcome, such as tumor size, exact tumor location, radia-
tion tolerance of the OARs, and (cardiovascular) co-morbidity. It 
has, therefore, been proposed to test early efficacy and toxicity of 
radiotherapy interventions in a randomized fashion (5).
Radiotherapy interventions are complex interventions, the 
evaluation of which is complicated by dependence on operator 
and team, learning curves and differences in levels of experience, 
and quality control. From this perspective, they resemble surgical 
innovations (8). In 2009, the Balliol consortium proposed recom-
mendations for the assessment of surgical innovations, based on a 
five-stage description of the surgical development process called 
IDEAL (Idea, Development, Exploration, Assessment, and Long-
term evaluation) (9). IDEAL aims for undelayed clinical imple-
mentation of superior interventions, without exposing patients to 
unnecessary risks. Recently, an IDEAL approach was proposed for 
systematic evaluation of medical devices (IDEAL-D) (10). In the 
present paper, we describe an IDEAL-based stepwise approach 
for evaluation of radiotherapy innovations (R-IDEAL), using 
examples from a recent innovation in radiation oncology—the 
MRI-guided linear accelerator (MR-Linac).
Mri-GUiDeD LiNeAr AcceLArAtOr
In 1999, researchers at the UMC Utrecht conceptualized the 
Magnetic Resonance-guided linear accelerator (MR-Linac) 
(11). The MR-Linac system comprises a 6-MV Linac (Elekta 
Instrument AB, Stockholm, Sweden) mounted on a ring around 
a 1.5-T MRI scanner (Achieva, Philips Healthcare, Amsterdam, 
the Netherlands) and an online adaptive radiotherapy planning 
system (11) (Supplementary material). The system is designed 
to image patients and irradiate them simultaneously. The 
accelerator and MRI are designed to be magnetically decoupled 
so that the MR images are not distorted by the presence of 
magnetized accelerator components, and the operation of the 
accelerator is not hampered by the magnetic field. A series of 
MR sequences can be performed to produce pre-, during- and 
post-treatment images. Once the MR-Linac is fully developed, 
the pre- and post-treatment MRI will include morphological 
and functional images. The system provides real-time soft-tissue 
imaging during treatment delivery and allows tumor tracking 
for high-precision targeting (12). Theoretically, more precise 
targeting enables dose escalation leading to improved local 
control and survival. Higher precision permits the use of smaller 
margins and may result in lower toxicity. MR-Linac also has the 
potential to allow non-invasive ablative radiotherapy treatment 
for tumor sites where stereotactic ablative radiotherapy is not 
routine practice.
For the purpose of systematic evaluation of innovations in 
radiation oncology, including MR-Linac, we adapted the IDEAL 
framework. Here, we took into account that, in contrast to sur-
gery, radiotherapy innovations often require simultaneous imple-
mentation of other technologies (i.e., hardware, software). Also, 
unlike surgery, effects of radiotherapy can be accurately modeled 
(13). R-IDEAL has been adopted by an international consortium 
to work toward coordinated and evidence-based introduction of 
the MR-Linac (14). The MR-Linac consortium was set up in 2012 
and consists of collaborators of seven large cancer institutions 
in Europe and North America and two companies (Elekta and 
Philips). Nine tumor-site working groups are currently identify-
ing clinical scenarios where MR-Linac technology (theoretically) 
could be of the most benefit for patients in terms of higher cure 
rates and/or lower toxicity. Each group works toward these goals 
by designing studies according to the adapted IDEAL framework 
(R-IDEAL).
tHe r-iDeAL stAGes
R-IDEAL closely resembles the original IDEAL recommenda-
tions (9). Since most radiotherapy innovations may be used at 
different disease sites and for different indications (i.e., margin 
reduction, dose escalation, etc.), some R-IDEAL steps may need 
to be repeated for the same tumor site. Some stages may also 
overlap between tumor sites, making some steps redundant for 
certain indications.
stage 0: radiotherapy Predicate studies
Stage 0 covers all preparatory work needed before the innovation 
is ready for clinical use (Table 1). We differentiate two types of 
Stage 0 studies. Some Stage 0 studies address the issue on how the 
innovative treatment will be delivered, including development of 
contouring atlases and new coils, assessment of inter-operator 
variation, and optimization of imaging sequences.
tABLe 1 | r-iDeAL stages for systematic evaluation of innovations in radiation oncology.
radiotherapy—
predicate studies
idea Development exploration Assessment Long-term 
evaluation
stage 0 stage 1 stage 2a stage 2b stage 3 stage 4
Purpose Answer the following 
questions before 
actual use of the 
innovation for 
treatment of patients
 1. How to use 
the innovation 
(software, coils 
needed)?
 2. Why and in 
whom to use the 
innovation?
First time use of 
the innovation for 
treatment delivery 
in men
Technical 
optimization of 
the innovation for 
treatment delivery
Provide proof of early clinical 
effectiveness and safety of the 
innovation
Formal comparison 
of innovation against 
standard treatment
Long-term outcomes 
of the innovation, 
post-marketing, and 
surveillance
Outcomes  – MR sequences, 
dedicated coils, 
etc.
 – Inter-rater 
reproducibility
 – Treatment 
strategies, patient 
selection
Proof of concept Technical 
improvements, 
feasibility, and 
safety
Early effectiveness
 – toxicity
 – tumor response
 – local recurrence (with spacious 
information)
Effectiveness compared 
to standard treatment
 – (disease-free) 
survival
 – recurrence
 – toxicity
 – PROMs, CTC-PRO,
 – Cost effectiveness
Long-term toxicity, 
long-term (disease-
free) survival, rare side 
effects, Patient-
Reported Outcomes
Study 
design
Phantom studies, 
delineation studies, 
planning studies, 
model-based studies
Structured case 
report
Prospective small 
uninterrupted case 
series
Prospective study with preferably 
randomized component: RCT; 
cmRCT; random allocation of limited 
available treatment slots to eligible 
patients; Comparison with matched 
(historical) controls
RCT, cmRCT, registry-
based trial
Prospective registries, 
including all patients 
treated with the 
innovation
Example Inter- and 
intraobserver 
reproducibility of MR 
versus CT delineation 
of the gross tumor 
volume in esophageal 
cancer
 1a. MR-Linac 
delivered 
conventional 
palliative 
radiotherapy 
for metastatic 
esophageal 
cancer
 1b. MR-Linac 
delivered 
neoadjuvant 
chemoradiation 
with reduced 
PTV margins for 
Stage IIB–IIIB 
esophageal 
cancer
Small prospective 
cohort study of 
10–20 patients 
with Stage IB–
IIIC esophageal 
cancer undergoing 
MR-Linac delivered 
neoadjuvant 
chemoradiation 
using standard 
fractionation (23–
28 times 1.8 Gy) 
with reduced PTV 
margins, with the 
aim to optimize 
technology and 
provide additional 
evidence of safety
A randomized study in patients with 
Stage IB–IIIC esophageal cancer 
who will be treated with neoadjuvant 
chemoradiation using standard 
fractionation (23–28 times 1.8 Gy), 
with reduced PTV margins delivered 
on the MR-Linac versus treatment 
with conventional margins delivered 
on a linear accelerator. Outcomes 
include pCR, 2-year mortality, 
recurrence, and toxicity
Multicenter RCT 
comparing mid- and 
long-term survival, 
toxicity, quality of life, 
and cost-effectiveness 
of MR-Linac delivered 
standard fractionation 
with reduced PTV 
margins versus 
standard radiotherapy 
of patients with Stage 
IB–IIIC esophageal 
cancer
The MR-Linac 
consortium has 
committed to 
registering technical 
data, patient and 
tumor characteristics, 
imaging, treatment, 
local control, survival, 
and toxicity in a 
collaborative registry
Adapted from McCulloch et al. (9).
For some innovations in radiation oncology, two levels of Stage 1 can be identified. In the case of MR-Linac, in Stage 1a, the technique is used for the first time to deliver standard 
treatment (standard dose and fractionation) in 1 to 3 patients to test the feasibility of using a linear accelerator in a magnetic field at a certain tumor site. In Stage 1b, for the first time, 
a different treatment strategy (e.g., dose escalation or margin reduction) is applied at a specific tumor site.
Stage 2a may follow Stage 1a (technical optimization of the innovation for standard dose delivery and fractionation) and Stage 1b (technical optimization of the innovation for a new 
indication, for example, dose escalation or margin reduction).
RCT, randomized controlled trial; cmRCT, cohort multiple randomized controlled trial.
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An example of a Stage 0 study for MR-Linac, is a study 
in which we compare inter-observer reproducibility 
of MR delineation versus CT delineation of the gross 
tumor volume in oesophageal cancer. Planning stud-
ies assess the effect of the 1.5T magnetic field on dose 
distribution.
Other Stage 0 studies answer the question on why the 
technique is used. What is the expected benefit of using this 
new technique instead of the standard treatment (higher cure 
rates, lower toxicity, or both)? Which patient categories and 
tumor types are expected to benefit most? For this purpose, the 
effect of dose escalation on tumor response and/or the effect 
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of margin reduction on healthy tissue toxicity is modeled (13). 
This allows prediction at which tumor sites and with which 
strategies the new innovation is likely to be of most benefit. 
Also, these modeling studies give an indication whether it is 
safe for the technique to be translated to clinic. Early health 
technology assessment studies may indicate which treatment 
strategies can be expected to be cost effective or how much 
more effective the innovation needs to be to justify the extra 
costs (15).
Another example of a Stage 0 study in silico planning 
studies will compare dose distributions to OAR between 
MR-Linac and conventional dose distribution, in order 
to predict the potential reduction in radiation-induced 
side effects by reduction of the PTV margin.
The number of patients included in Stage 0 depends on 
the type and aim of the study. Development of coils may only 
require healthy volunteers, MRI sequence optimization and 
reproducibility studies typically include around 20–40 patients, 
while some other studies, like model-based approach, require no 
volunteers or patients at all. Outcome of Stage 0 include reports 
on inter-observer reproducibility, delineation studies, modeling 
studies, and early health technology assessment studies.
stage 1: idea
In this Stage, the innovation is used for the first time at a certain 
tumor site in a patient (Table 1). Stage 1 demonstrates feasibil-
ity and absence of unexpected detrimental effects. Patients in 
Stage 1 are highly selected and perfect candidates for the 
intervention. Successful completion of the procedure, as well as 
unexpected technical and clinical complications will be reported 
as a case report. Systematic reporting of all results of Stage 1 
studies allows groups to learn from each other and prevent 
similar (technical) complications. Since unexpected toxicity may 
occur up to months after the intervention, depending on OARs, 
a follow-up time needs to be incorporated before proceeding to 
Stage 2a. After Stage 1, it may be necessary to go back to Stage 0 
to address technical problems.
stage 2a: Development
After Stage 1 has shown technical feasibility, without major unex-
pected toxicities or complications, the technique enters Stage 2a 
(development) (Table  1). Stage 2 aims to refine the technique 
and to optimize the work-flow. Stage 2a includes 10–30 patients. 
Outcomes of this Stage are technical feasibility and safety.
In Stage 2a, planned and unplanned technical modifica-
tions can be made. Details and timing of these modifications 
are reported, providing other groups with potentially helpful 
information for the use of the innovation at other tumor sites. 
All patients are reported consecutively, including unsuccessful 
or canceled interventions and reasons for that. Reports contain 
inclusion criteria, proportion of eligible patients treated with the 
new innovation, clear descriptions of each procedure, technical 
modifications made (with timeline), and toxicity. Stage 1 and 
Stage 2a may be submitted for ethical approval at the same time, 
with predetermined stopping rules, safety monitoring, and rules 
for when to move on to the next Stage or reiteration of the previ-
ous Stage.
For some radiotherapy innovations, two levels of Stage 1 and 
Stage 2a can be identified. In the case of MR-Linac, in Stage 1a, 
MR-Linacs used for the first time to deliver standard dose and 
fractionation in 1 to 3 patients to test the feasibility of using a 
linear accelerator in a magnetic field at a certain tumor site.
An example of a Stage 1a study is a study where 
MR-Linac delivered palliative radiotherapy using 
conventional margins and fractions (5 times 4 Gray) is 
administered to 1-3 patients with metastatic esophageal 
cancer to demonstrate feasibility of standard treatment 
of MR-Linac
After MR-Linac has been used for the first time for standard 
dose delivery and fractionation (Stage 1a), technical refinement 
and optimization of the work-flow for standard dose delivery and 
fractionation will be performed in Stage 2a.
An example of Stage 2a is a small prospective cohort 
study including 10-20 patients with metastatic esopha-
geal cancer who receive MR-Linac-delivered palliative 
radiotherapy using conventional margins and fractions 
(5 times 4 Gray)
After technical details and workflow of the technique for 
standard treatment delivery have been optimized, the assessment 
procedure proceeds to Stage 1b. In Stage 1b, for the first time, 
a different treatment strategy (dose escalation or margin reduc-
tion) is applied at a specific tumor site. Stage 1b, like Stage 1a, 
includes 1–3 highly selected patients, who are perfect candidates 
for the intervention.
An example of a Stage 1b study is a study including 
1-3 patients with stage IB-IIIC esophageal cancer who 
undergo MR-Linac delivered neoadjuvant chemoradia-
tion using standard fractionation (23-28 times 1.8 Gray) 
with reduced PTV margins
After a proof of concept for this innovative approach has 
been demonstrated, the technique re-enters Stage 2a, in which 
additional modifications are made to further optimize work-flow 
and technology for innovative treatment delivery.
An example of a Stage 2a study is a small prospective 
cohort study of 10-20 patients with stage IB-IIIC 
esophageal cancer who undergo MR-Linac delivered 
neoadjuvant chemoradiation using standard fractiona-
tion (23-28 times 1.8 Gray) with reduced PTV margins
stage 2b: exploration
After the main technical details have been worked out, the focus 
of the R-IDEAL assessment procedure shifts from technical 
optimization to evaluation of clinical effectiveness. In Stage 
2b, evidence of early efficacy is provided (Table  1). Outcomes 
in Stage 2b depend on tumor site and may include clinical and 
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pathological tumor response, toxicity, early tumor recurrence, 
and (disease-free) survival. Spatial information is collected in 
case of early local recurrence. Recurrence in the center of the 
tumor suggests under-dosing while recurrence at the periphery 
of the tumor suggests too narrow margins. Studies in Stage 2b 
typically have a follow-up period of 18–24  months. Based on 
the outcomes of Stage 2b, investigators may need to go back to 
Stage 2a, to address technical issues, or even Stage 0, to improve 
treatment strategy and patient selection.
Stage 2b preferably adopts a randomized design, such as a 
randomized controlled trial. The reason for this is that many 
factors may affect efficacy and toxicity, such as exact tumor size, 
anatomic site, radiation tolerance of OARs, and comorbidities. 
Usually, the number of treatments that can be delivered using the 
new innovation is limited when the technique is first introduced 
(limited amount of treatment slots). This provides a unique 
opportunity for randomized evaluation, as the limited available 
treatment slots may be randomly allocated to eligible patients. If, 
for example, in a certain week two treatment slots for a certain 
tumor site are available, while there are five eligible new patients, 
two patients will be randomly selected for treatment on the 
MR-Linac, while the other three receive standard care. In the next 
week, with two available treatment slots and three eligible new 
patients, two patients are randomly allocated to MR-Linac treat-
ment. This period-stratified random sampling of a predetermined 
fixed number of patients from a variable sized “dynamic” pool 
will bring a randomized component in the comparison, reduce 
the potential for selection by indication, and maximize the use 
of the available slots. If, due to time and financial constraints, 
randomization is not feasible, prospective registries or cohort 
studies, with matched (historical or contemporary) controls, may 
be good alternatives.
In Stage 2b, quality control measures will be reported to 
provide clear understanding of the accuracy with which the 
procedure has been performed.
An example of a Stage 2b study is a randomized trial, 
including patients with stage IB-IIIC esophageal cancer. 
The intervention arm will be treated on MR-Linac and 
receive neoadjuvant chemoradiation using standard 
fractionation (23-28 times 1.8 Gray) and reduced PTV 
margins. The control arm is treated on a standard linear 
accelerator and receives neoadjuvant chemoradiation 
using standard fractionation (23-28 times 1.8  Gray) 
with conventional margins. Both groups are compared 
in terms of pathological complete response (pCR) rates, 
2 year mortality, early recurrence, and toxicity.
stage 3: Assessment
When Stage 2b has provided early evidence that the innovation 
may accomplish the radiation treatment more effectively or with 
fewer side effects, the treatment will be compared against standard 
therapy (Table 1). The randomized control trial (RCT) remains 
the design of choice. However, RCTs may be challenging due to 
recruitment difficulties, strong doctor and patient preferences, 
different perceptions of equipoise, and limited capacity of the 
new equipment (16, 17). Alternative designs may be considered, 
including the registry-based RCT (18) or the cohort multiple 
RCT (19). In these designs, prospective cohorts or registries serve 
as facilities for (multiple) pragmatic randomized comparisons of 
new interventions against standard treatment.
Outcomes of Stage 3 include (disease-free) survival, recurrence, 
tumor response, and toxicity and cost-effectiveness. In addition to 
these outcomes, the perspective of the patient (i.e., quality of life, 
fatigue, workability) provides valuable and complementary input, 
and a more robust appreciation of patients’ symptoms (20). The 
patient-reported outcomes version of the Common Terminology 
Criteria for Adverse Events (PRO-CTCAE) intertwines the 
patient perspective directly into the AE reporting system (21, 22) 
and gives an accurate estimation of treatment-induced toxicity.
Stage 2b and 3 may be submitted as a single protocol, with 
clear definition of stopping rules. When Stage 3 shows negative or 
neutral results for the indication under study, introduction into 
regular care is not justified (not evidence-based).
An example of a Stage 3 study is a multicenter RCT 
including patients with stage IB-IIIC esophageal cancer. 
The intervention arm will be treated on MR-Linac and 
receive neoadjuvant chemoradiation using standard 
fractionation (23-28 times 1.8 Gray) and reduced PTV 
margins. The control arm is treated on a standard linear 
accelerator and receives neoadjuvant chemoradiation 
using standard fractionation (23-28 times 1.8  Gray) 
with conventional margins. Both groups are compared 
in 5 year survival, toxicity, quality of life and cost 
effectiveness.
stage 4: Long-term study
Prospective registries will be set up to capture technical, clinical, 
treatment, and outcome data of patients who underwent the 
new intervention, allowing large-scale evaluation of long-term 
effectiveness and rare side effects (Table 1). Also, variations in 
outcomes between institutions can be assessed, which may be 
indication of differences in quality assurance or patient selection. 
All patients who have been exposed to the innovations, starting 
at Stage 1, will enter the registry. The registry is setup in such a 
way that it also allows data exchange between institutions who 
have invested in the innovation, using high standards for data 
interoperability, quality control, privacy, and data ownership (23).
The MR Linac consortium has committed to registering 
technical data, patient and tumor characteristics, imag-
ing, treatment, local control, survival, and toxicity in a 
collaborative registry.
DiscUssiON
We adapted the IDEAL framework to fit the radiotherapy setting 
and encourage systematic evaluation of innovations in radiation 
oncology. Innovations in radiation oncology vary from minor 
technical adaptations, i.e., new MRI sequences or new coils, to 
major innovations with large potential therapeutic and societal 
impact. History has shown that technical innovations in the areas 
of surgery and radiotherapy run a high risk of being implemented 
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without rigorous evaluation. Introducing a new technology 
implicates changes in imaging modalities and/or workflow, need 
for new software, quality assurance, training of the multidiscipli-
nary team, and development of team expertise. New technologies 
frequently imply significant investment for the developer and the 
user. Therefore, evaluation for radiotherapy innovations is more 
complex than pharmaceutical innovations, where investment on 
the whole is only made by the developer. The need for users to 
have returns on their investment, both financial and professional, 
frequently compromises the evaluation of the technology and can 
fuel non-evidence-based use. The use of protons has increased 
exponentially in the last few years. However, theoretical advantages 
of proton therapy have not yet been confirmed in randomized 
trials. A study among 27,647 Medicare recipients with prostate 
cancer (553 of whom were treated with proton therapy) showed 
that although proton therapy was substantially more costly, there 
was no measurable reduction in toxicity at 12 months posttreat-
ment (24). Nonetheless, proton therapy is being offered to a grow-
ing number of patients, often on their demand. Similarly, IMRT is 
widely used, although its exact benefit is not known for all clinical 
indications. Several studies have shown reduced toxicity for head 
and neck (4, 25) and breast cancer (26). For many clinical indica-
tions, superiority of IMRT has not been proven, or was proven 
only after IMRT was widely adopted (27). Also, the impact of 
an increase in the volume proximal to the tumor receiving a low 
radiation dose on the induction of secondary tumors has been 
insufficiently investigated.
Like IMRT, proton therapy, and MR-Linac, most technical 
innovations in radiation oncology can be used for different 
indications and at different sites. The R-IDEAL framework 
accelerates identification of areas where the new technology 
is likely to be of most benefit, and areas where the new tech-
nology is not feasible (Stage 1, 2a), not (more) effective (than 
standard therapy) (Stage 2b, 3) or associated with long-term 
adverse effects (Stage 4). Early abandonment of development 
of new technologies for unsuitable indications, and prevention 
of implementation, will reduce costs and harms and allow the 
focus to be shifted to areas where the technique is more likely to 
provide benefit. This is in the interest of vendors, users, patients 
and society. Finally, the R-IDEAL framework is not (primarily) 
intended as a mechanism to support regulatory clearance, but 
rather as a process and strategy to iterate an innovative tech-
nology. While the regulatory process is independent from the 
R-IDEAL process, there are some common elements between 
the two. In the case of MR-Linac, a good example is the develop-
ment of imaging sequences which is part of R-IDEAL and is also 
necessary for 510(k) clearance.1
In conclusion, the R-IDEAL framework was adapted to fit the 
radiation oncology setting in order to facilitate systematic evalu-
ation of innovations in radiation oncology. R-IDEAL holds the 
promise for timely, evidence-based introduction of radiotherapy 
innovations with proven superior effectiveness, while prevent-
ing unnecessary exposure of patients to potentially harmful 
interventions.
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